Eye health guide

Which distinctions matter for this goal?

Consider macular degeneration, dry eye and deficiency-related night blindness separately. Eye studies discussed in the TB-500 guide concern full-length thymosin beta-4; they are not human trials of TB-500. A single ingredient is not equivalent to the combined AREDS formula.

Who was studied in AREDS2?

AREDS and AREDS2 were not general trials of “vitamins for stronger eyes.” They studied progression at particular stages of age-related macular degeneration (AMD). NEI describes benefit in intermediate AMD or certain advanced-disease situations, without the same benefit in people with no AMD or early AMD. The formulation does not prevent the disease or serve as a treatment that restores vision already lost. ^[2]

A healthy person working long hours at a screen and someone diagnosed with intermediate AMD are therefore asking different questions. A strong evidence grade does not mean everyone needs that formulation. Suitability depends on the condition and stage established through eye assessment.

A single ingredient is not the studied formulation

The presence of lutein and zeaxanthin in a trial does not mean every product containing these two ingredients reproduces all AREDS2 results. The other ingredients, comparator and participant characteristics matter. NEI also states that older beta-carotene formulations are not recommended for current or former smokers; the use of lutein and zeaxanthin in AREDS2 is part of this distinction. ^[2]

An “eye vitamin” label does not establish equivalence with the researched formula. Compare the whole preparation rather than the amount of one ingredient. This guide does not select a product or personal dose.

Why separate dry eye from vision loss?

Dry-eye symptoms, progression of retinal disease and problems caused by a deficiency are distinct outcomes. Omega-3, vitamin A and lutein cards should not be merged into a general “better vision” claim. A finding about AMD progression, for example, does not demonstrate a reduced spectacle prescription or relief of screen fatigue.

Research-peptide cards require the same care: a result cannot be transferred without matching the substance, formulation and eye condition studied. A cellular or tissue-repair mechanism does not establish preserved vision in people. The useful comparison starts with the condition and outcome, before the grade.

An important detail in the AREDS2 result

AREDS2 enrolled 4,203 people at risk of advanced AMD. Lutein/zeaxanthin, omega-3 or both were added to an existing AREDS formulation. In the primary analysis over five years, the additions did not significantly reduce progression to advanced AMD. Replacing beta-carotene with lutein/zeaxanthin is a different comparison. “A formula helps selected patients” therefore does not mean “adding every extra ingredient improves the formula.” ^[3]

Start with the condition and its stage

Before comparing supplements, identify the diagnosis studied. NEI’s AREDS2 advice depends on AMD stage established through an eye examination. Screen use, a need for glasses and AMD cannot be treated as one question. ^[1]

For example, two readers viewing the same lutein card may have intermediate AMD and discomfort after screen use, respectively. If the stronger result concerns the first situation, it does not answer the second. Match the condition, then the formulation and outcome.

When should you not wait?

A sudden increase in floaters, flashes of light or a curtain or shadow over vision can indicate retinal detachment. NEI advises immediate eye care or emergency assessment. Trying a supplement or waiting for the next routine appointment is inappropriate. ^[4]

Summary: which outcome, which limitation?

Detailed compound guides

• Lutein and Zeaxanthin: Slowing of progression in intermediate AMD — AREDS-type antioxidant vitamin–mineral formula; Preventing AMD (healthy people) — insufficient evidence.
• Vitamin A: Night blindness and xerophthalmia (in deficiency); Progression of macular degeneration (mixed formula).
• Omega-3: Dry eye — no benefit shown.
• Saffron: Age-related macular degeneration (single RCT).
• TB-500: Dry eye (full thymosin beta-4 eye drop) — no benefit shown; Neurotrophic keratopathy (full thymosin beta-4 eye drop) — no benefit shown.